Contents
On this page
- Definition of decentralised and home-based trial activities
- Adoption of decentralised methods in trials
- Differential uptake of remote consent and remote measurement
- Patient and professional perspectives on home testing
- Failure modes of home diagnostics
- Limitations of the evidence base
- Specification of a home-collected measurement
- Activity-level decision-making
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Data Analytics & AI · Home diagnostics in trials
Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence
Moving a diagnostic test into a participant’s home alters three elements simultaneously: who handles the sample, who observes the participant, and what happens when the measurement fails. Uptake data indicate that trials have adopted remote consent and remote visits considerably faster than remote testing, and expert analysis of decentralised activities identifies more weaknesses than strengths. Both findings are relevant to design decisions.
Home and remote diagnostics in trials are usually discussed as a matter of convenience; the published record indicates that they are principally a matter of measurement. Among registered drug trial protocols from 2019 and 2020, telemedicine visits were the most frequently reported decentralised data collection method at 52.4% and home health visits the least frequent at 7.9%, with wearables or biomarker kits at 15.8%. Trials have therefore readily moved communication into the home but have been considerably slower to move measurement, an appropriate degree of caution for the reasons set out in this article.
Learning objectives
- The legal definition of a decentralised trial, and the reasons “fully decentralised” constitutes a narrow category
- The decentralised methods that trials have and have not adopted, and the gradient across trial phases
- The specific failure modes of home sample collection, remote screening and self-monitoring devices
- The reasons patient-reported advantages of home testing do not correspond to the factors that drive patient decisions
- What the systematic review evidence can and cannot support regarding decentralised methods
- Specifying a home-collected measurement in a protocol so that both an inspector and a statistician can work with it
Common misconceptions
- “Decentralised means the trial has no site.” US law (the Food and Drug Omnibus Reform Act, FDORA) defines a decentralised clinical trial as one in which study activities occur at a location separate from the investigator’s location, with fully decentralised designs holding all activities away from the site. In registered protocols, on-site data collection was still reported in 98.4% of cases and only 1.6% were decentralised only.
- “Home testing is mainstream now.” Remote contact is widespread; remote measurement is not. Telemedicine visits were reported in 52.4% of protocols, patient-reported outcomes in 41.7%, wearables or biomarker kits in 15.8% and home health visits in 7.9%.
- “Patients want home testing because it is convenient.” A two-country qualitative study of home- and remote-based testing found that convenience did not influence patients’ decisions in the way the argument for remote testing assumes, even though comfort and convenience were named among its main advantages. These are distinct claims with different design implications.
- “A home result is the same measurement taken somewhere cheaper.” It is a different measurement. Home collection and transport risk sample deterioration or contamination; remote screening without an in-person examination risks missing underlying conditions; and self-monitoring device failures produce data problems that no analysis can recover.
- “The evidence shows decentralised methods work as well as on-site.” A systematic review of decentralised trial methods screened 18,553 records and assessed 237 full texts, but found the trials too heterogeneous for meta-analysis. No pooled estimate exists, and any pooled estimate cited derives from a different source.
Definition of decentralised and home-based trial activities
The definitional anchor is now statutory in the United States. Under FDORA, a decentralised clinical trial is one in which study activities occur at a location separate from the investigator’s location, and a fully decentralised design is one in which all activities are held away from the site 1,4. That phrasing merits careful reading, because it defines the concept by location of activity rather than by technology. A home health visit by a trial nurse is decentralised; a video consultation is decentralised; a wearable streaming data from a participant’s wrist is decentralised. They have almost nothing else in common.
This matters because the operational and statistical consequences differ fundamentally among these three. A home visit relocates a trained observer. A video visit removes physical examination but retains the clinician. A wearable removes the observer entirely and substitutes an instrument whose failure is silent. Any analysis that treats “decentralisation” as a single entity will mislead, which partly explains why pooled evidence does not exist.
The practical consequence for a protocol is that the unit of decision is the activity, not the trial. For each activity proposed for relocation — consent, screening, dosing, sample collection, endpoint assessment, safety monitoring, drug accountability — the question is what the site was providing beyond a room, and whether anything replaces it. Pubrica’s protocol work and page on trial quality strategies set out how to run that analysis activity by activity.
Adoption of decentralised methods in trials
Among 254 registered drug trial protocols from 2019 and 2020, decentralised data collection was reported in 68.9% while on-site data collection was reported in 98.4% — and only 1.6% were decentralised only 11. The typical configuration is therefore hybrid, and it is the hybrid that must be designed well 4,11.
The method mix is the informative element. Telemedicine visits were the most frequently reported method at 52.4%, followed by patient-reported outcomes at 41.7%, wearables or biomarker kits at 15.8%, and home health visits least at 7.9%. The ordering is almost exactly the inverse of clinical intrusiveness: the activities most easily relocated are those in which nothing is physically handled, and the most difficult is the one that requires a trained person in the participant’s home.
There is also a clear phase gradient. Decentralised data collection was reported in 81.9% of phase 3 protocols, 73.3% of phase 2 and 47.0% of phase 4. The leading position of phase 3 is not what a naive reading would predict — large confirmatory trials are usually the most conservative — and the likely explanation is scale: a phase 3 programme running at hundreds of sites has the most to gain from reducing visit burden, and the budget to validate the alternative.
Where therapeutic-area data exist, the direction is the same but the baseline is low. The share of neurology trials using digital health technologies rose from 0.7% in 2010 to 11.4% in 2020 7,14. That is a sixteen-fold increase over a decade, and it still leaves roughly nine in ten neurology trials using none. Both observations are accurate, and most commentary cites only one.
Decentralised data collection methods reported in registered drug trial protocols
| Method | Share of protocols reporting it |
|---|---|
| Telemedicine visits | 52.4% |
| Patient-reported outcomes | 41.7% |
| Wearables or biomarker kits | 15.8% |
| Home health visits | 7.9% |
| Any decentralised data collection | 68.9% |
| On-site data collection | 98.4% |
| Decentralised only | 1.6% |
From 254 registered drug trial protocols dated 2019 to 2020. Methods are not mutually exclusive; a protocol could report several. The ordering tracks clinical intrusiveness almost exactly in reverse.
Adoption at two levels. The neurology figures track digital health technology use across a decade. The protocol figures come from 254 registered drug trial protocols dated 2019 to 2020, in which decentralised data collection was reported by 81.9% of phase 3, 73.3% of phase 2 and 47.0% of phase 4 protocols.
Differential uptake of remote consent and remote measurement
The most pronounced movement in the protocol data is not in testing at all. Decentralised consenting rose from 4.2% of protocols in the first half of 2019 to 20.9% in the first half of 2020, while on-site consenting fell from 99.4% to 81.4% over the same period 11,12. Direct-to-patient shipment of investigational medicinal product peaked at 14.0%.
Two conclusions follow. First, the fact that on-site consenting was still reported in 81.4% of protocols while decentralised consenting reached 20.9% confirms the hybrid picture: many protocols permitted both. Second, the rapidity of the consent shift relative to the testing shift is a reasonable proxy for how the field perceives risk. Remote consent is a process change with legal and documentation requirements; remote measurement is a change to the data. Teams adopted the first quickly and the second slowly, which is defensible.
In the design of remote consent, the principal effort lies in documentation — identity verification, evidence that the participant had the opportunity to ask questions, a retrievable record of the version consented to, and a route for participants without the devices or connectivity the process assumes 1,17. Our informed consent documentation work covers these and the SPIRIT items cover where they go in the protocol.
Movement in consenting and drug supply over the study window
| Measure | First half 2019 | First half 2020 |
|---|---|---|
| Decentralised consenting | 4.2% | 20.9% |
| On-site consenting | 99.4% | 81.4% |
| Direct-to-patient investigational product shipment | — | Peaked at 14.0% over the window |
Same protocol sample of 254 registered drug trials. On-site consenting remaining at 81.4% alongside decentralised consenting at 20.9% indicates protocols permitting both routes rather than a wholesale switch.
Patient and professional perspectives on home testing
A two-country qualitative study in Spain and Brazil interviewed 47 people — 37 patients, 2 caregivers and 8 healthcare professionals — and ran a validation workshop with 32 more, comprising 13 patients, 7 caregivers and 12 healthcare professionals 8,11. It produced five themes, supported by a literature component in which 47 articles were identified, 30 assessed and 16 found relevant.
Participants identified three main advantages of home- and remote-based medical testing: comfort and convenience, better clinician-patient relationships, and greater disease awareness 8. The second merits attention because it is counter-intuitive — removing the clinic visit was described as improving rather than degrading the relationship, plausibly because the interaction that remains is the consultation rather than the logistics.
The study also found that convenience did not influence patients’ decisions in the way remote-testing arguments assume 8. This does not contradict the list of advantages; it reflects the distinction between what people value about an option and what drives their choice. The design implication is specific: a protocol justified mainly on reduced participant burden may not improve retention as much as the justification implies, and retention assumptions should not be based on convenience alone 8,9. This illustrates the kind of assumption that only qualitative work can falsify — see the page on qualitative research in trials.
Failure modes of home diagnostics
A structured SWOT analysis of eight key decentralised trial activities, carried out by ten experts at a 2022 workshop, named failure modes rather than generic risks 3. Three are directly relevant to home diagnostics.
Sample integrity. Home collection and transport of samples risks deterioration or contamination 3. The failure is usually silent: the sample arrives, is analysed, and returns a plausible but incorrect value. Unlike a missing sample, a degraded one enters the dataset. Mitigations are routine and must be designed in — stability windows specified for the actual courier timeline rather than the ideal one, temperature logging, explicit acceptance criteria, and a rule for the handling of out-of-window samples that is written before the first one arrives.
Remote screening. Screening without an in-person examination risks missing underlying conditions 3. A site visit never provided only the protocol-specified assessments; it also gave a clinician the opportunity to notice something that no one had thought to measure. Removing it shifts eligibility from examined to reported, which affects both safety and the comparability of the enrolled population.
Self-monitoring devices. Device failures generate data problems that no analysis fully recovers — gaps that are not missing at random, because a device fails more often for the participants least able to troubleshoot it, and plausible values produced by a miscalibrated instrument 3,7. The analytic consequence is that missingness in home-collected data needs a stated mechanism assumption and a sensitivity analysis, not a default imputation.
The overall profile of that expert analysis is itself a finding: ten experts examining eight activities generated 62 weaknesses against 48 strengths, condensing to 13 weakness categories against 11 strength categories, with only 5 opportunities raw and 2 categorised. The risks in this field are currently better enumerated than the benefits.
Named failure modes for home and remote activities, and what each requires in the protocol
| Activity | Failure mode identified | What the protocol must specify |
|---|---|---|
| Home sample collection and transport | Sample deterioration or contamination — typically silent, producing a plausible wrong value rather than a missing one | Stability window against the real courier timeline, temperature logging, acceptance criteria, and the rule for out-of-window samples |
| Remote screening | Missing underlying conditions that an in-person examination would have detected | What replaces incidental clinical observation, and how eligibility shifts from examined to reported |
| Self-monitoring devices | Device failure generating data problems that analysis cannot recover, including non-random gaps and miscalibrated plausible values | Missingness mechanism assumption, pre-specified sensitivity analysis, plausibility limits and a troubleshooting route |
Failure modes from a structured SWOT analysis of eight key decentralised trial activities by ten experts at a 2022 workshop. That exercise generated 62 weaknesses against 48 strengths in raw form, condensing to 13 weakness categories against 11 strength categories.
Limitations of the evidence base
The evidence is less substantial than the enthusiasm. A systematic review of decentralised trial methods identified 19,704 records, screened 18,553, assessed 237 full texts, and included 45 trials in the quantitative analysis alongside 117 documents in a qualitative analysis that produced four themes 9. Its central methodological finding was that the trials were too heterogeneous to meta-analyse 9.
This is a legitimate result, and it constrains what can be claimed. There is no pooled estimate of the effect of decentralisation on retention, data quality, recruitment speed or cost, because the included trials differ in which activities they moved, which conditions they studied, which technologies they used and what they measured 9. Any statement of the form “decentralised trials achieve X% better retention” is not supported by this literature.
What the review does support is a narrative account of recurring themes, with the caveat that participant and stakeholder experience was incompletely represented across the documents analysed 9. For a sponsor making a design decision, the implication is that the case for a specific decentralised element must be made on mechanism and on the sponsor’s own feasibility data, not by citing a field-level effect that does not exist. Pubrica’s systematic review and meta-analysis teams frequently observe this pattern: heterogeneity that precludes pooling is a finding, not a failure of the review.
Specification of a home-collected measurement
Five elements must be specified in the protocol for a home-collected measurement to be analysable.
The measurement, not the device. What quantity is being measured, in what units, under what conditions, at what time of day, in what physiological state. A device model is not a measurement specification; two models measuring the same quantity can disagree systematically 18,23.
Agreement with the reference method. If the trial’s endpoint or a historical comparison depends on a laboratory or clinic measurement, the home method requires a documented agreement relationship — ideally from a bridging sub-study in the trial’s own population rather than a manufacturer’s data in a different one 6,23. The acceptable level of agreement should be stated before the data are examined.
Acceptance criteria and a failure rule. What makes a result usable: stability window, temperature range, completeness, plausibility limits. And what happens when a result fails them — repeat, impute, exclude, escalate — decided in advance, because a decision made afterwards is a protocol deviation with a selection effect.
The missingness mechanism. The assumption and its rationale should be stated, and a sensitivity analysis under a different assumption pre-specified. Device-generated missingness is rarely missing completely at random 7.
The route back to a person. Whom the participant contacts when the kit does not work, how quickly, and what the site does with a result that is clinically actionable. A home result that triggers no clinical pathway is a safety gap.
Where the home measurement is a device-derived endpoint, there is also a regulatory dimension — see Pubrica’s medical device and IVD work and diagnostics industry page. For the statistical handling, biostatistics and the analysis plan are the right entry points.
The home sample collection paragraph in a protocol (values below are illustrative, to show the level of specification required)
Describes an intention
To reduce participant burden, blood samples at weeks 4, 12 and 24 will be collected at home using a self-collection device and returned to the central laboratory by post. Samples will be analysed using the same validated assay as site-collected samples. Participants will be trained in the use of the device at the baseline visit and provided with written instructions.
“Same validated assay” is not the same measurement. The assay may be identical while the specimen, the matrix and the pre-analytical handling are not, which is where the documented failure mode sits.
No stability window and no transport assumption. Deterioration in transit is the named silent failure for home collection, and nothing here constrains it.
No acceptance criteria. Without them, a degraded sample is analysed and enters the dataset as a plausible wrong value.
No agreement data. If home and venous values are used interchangeably, the agreement relationship is a premise of the analysis and it is unstated.
No missingness handling. Collection failures are not missing at random; a default imputation will be biased in the direction of the participants who found the device hardest to use.
No clinical pathway. A home result that is clinically actionable and reaches nobody is a safety gap, not a data gap.
Describes a measurement
Samples at weeks 4, 12 and 24 are self-collected using the specified capillary device and returned to the central laboratory by tracked courier. The analyte is stable for 72 hours at 2 to 30 degrees Celsius in the collection matrix; the courier contract guarantees delivery within 48 hours of collection for all participating postcodes, and each kit carries a single-use temperature indicator. A sample is accepted for analysis if the indicator is unbreached, the recorded collection-to-receipt interval is 72 hours or less, and the fill volume meets the device minimum; samples failing any criterion are reported as collection failures, not as missing at random, and the participant is offered one repeat collection within seven days. Agreement between home-collected and venous site-collected values has been established in a bridging sub-study of 60 participants from this trial population, with the Bland-Altman limits of agreement and the pre-specified acceptable limit stated in Appendix F; the primary endpoint is derived from site-collected samples at weeks 0 and 24, with home-collected values used for the secondary trajectory analysis only. The analysis plan assumes home-sample missingness is related to observed participant characteristics and includes a pre-specified sensitivity analysis under a missing-not-at-random assumption. Participants are trained at baseline with a teach-back check recorded in the case report form, and have a telephone route to the site during working hours; any home-collected value outside the pre-defined clinically actionable range is reported to the site within one working day and managed under the safety procedures in Section 8.
The measurement is specified as a measurement — matrix, stability, temperature, volume — so a laboratory and a statistician are working from the same definition.
Acceptance criteria and a repeat rule are decided in advance, which keeps the failure out of the dataset and the decision out of the hands of whoever opens the box.
Agreement is established in the trial’s own population with a pre-stated acceptable limit, rather than inherited from the manufacturer’s population.
The primary endpoint is kept on the reference method and the home measurement carries a secondary role, which is the conservative allocation when agreement data are new.
Missingness is treated as informative, with a pre-specified sensitivity analysis rather than a default.
The clinically actionable pathway is named with a time limit, which is what makes remote measurement safe rather than merely convenient.
An inspector will ask what happens to a sample that arrives warm, and a statistician will ask whether home and clinic values can be pooled. The first version answers neither question; the second answers both before the first kit is shipped, which is the only point at which the answers carry no cost.
Activity-level decision-making
The following decision procedure follows from the preceding sections.
First, list the activities rather than the trial, following the statutory framing: for each study activity, determine whether it occurs at the investigator’s location or elsewhere. Second, for each activity proposed for relocation, record what the site was providing beyond a room — observation, handling under controlled conditions, identity verification, immediate clinical response — and what replaces it. Third, check the relocation against the trial’s critical-to-quality factors: if the activity feeds the primary endpoint or eligibility, the validation burden is higher and bridging data are mandatory.
Fourth, state the justification accurately. If the reason is participant burden, note that the qualitative evidence does not support convenience as the driver of participant decisions, so retention gains should not be assumed 8. If the reason is recruitment reach, this should be stated, because it is a different claim with different evidence requirements. Fifth, plan the hybrid rather than the ideal: 98.4% of protocols reported on-site data collection, so the interface between home-collected and site-collected data should be designed explicitly, including how the two are reconciled when they disagree.
Key points
Key points
Home and remote diagnostics have been adopted unevenly, and the pattern is informative. Among 254 registered drug trial protocols, telemedicine visits were reported in 52.4%, patient-reported outcomes in 41.7%, wearables or biomarker kits in 15.8% and home health visits in only 7.9%, while on-site collection remained at 98.4% and only 1.6% of protocols were decentralised only. Trials have moved communication into the home faster than measurement, which is the appropriate order: the expert SWOT (strengths, weaknesses, opportunities and threats) analysis of eight decentralised activities identified sample deterioration in transport, missed underlying conditions on remote screening and unrecoverable device-failure data as specific rather than generic risks, and generated more weaknesses than strengths overall. No pooled effect estimate is available, because the systematic review that screened 18,553 records found the trials too heterogeneous for meta-analysis. Decisions should therefore be made activity by activity, recording what the site provided beyond a room, obtaining bridging agreement data in the study population, treating collection failure as informative missingness, and avoiding retention assumptions based on convenience, which the qualitative evidence indicates does not drive patient decisions.
Application to your study
Application to your study
- Assess activities individually rather than the trial as a whole. For each study activity, determine whether it occurs at the investigator’s location or elsewhere, and treat each relocation as a separate design decision with its own justification.
- Record what the site provided beyond a room. This includes observation, controlled handling, identity verification and immediate clinical response; the protocol should state what replaces each one.
- Specify the measurement, not the device. Define the quantity, units, matrix, timing, physiological state, stability window and temperature range before any kit is procured.
- Obtain bridging agreement data in the study population. A pre-stated acceptable limit of agreement should be used, and the primary endpoint should remain on the reference method until such data are available.
- Set acceptance criteria and a failure rule in advance. Define what makes a result usable and what follows when it is not (repetition, exclusion or escalation) before the first failure occurs.
- Treat home-data missingness as informative. State the assumed missingness mechanism, pre-specify a sensitivity analysis under an alternative assumption, and avoid default imputation of device gaps.
- Establish the clinical pathway for an actionable home result. Specify who is informed, within what period and under which safety procedure.
- Avoid justifying the design on convenience alone. The qualitative evidence indicates that convenience is valued but does not drive patient decisions, so retention gains are not a safe planning assumption.
Frequently asked questions
Under US law (FDORA), a decentralised clinical trial is one in which study activities occur at a location separate from the investigator’s location, and a fully decentralised design is one in which all activities are held away from the site. The definition is framed around location of activity rather than technology, which is why a home nursing visit, a video consultation and a wrist-worn sensor all fall within it despite having almost nothing operationally in common. In practical terms, decentralisation is not a property that a trial has or lacks; it is a property of each individual activity, and each one requires its own justification and its own mitigation.
Fewer than the discussion suggests, and the methods differ sharply in uptake. Among 254 registered drug trial protocols from 2019 and 2020, decentralised data collection appeared in 68.9% overall, but the mix was telemedicine visits 52.4%, patient-reported outcomes 41.7%, wearables or biomarker kits 15.8%, and home health visits only 7.9%. On-site data collection was still reported in 98.4% of protocols and just 1.6% were decentralised only. By phase, decentralised collection appeared in 81.9% of phase 3 protocols, 73.3% of phase 2 and 47.0% of phase 4. Separately, digital health technology use in neurology trials rose from 0.7% in 2010 to 11.4% in 2020 — a steep rise from a very low base.
Not by assumption, and the burden is on the protocol to establish it. The identified failure mode for home collection and transport is deterioration or contamination, and it is usually silent: the sample arrives, is analysed and yields a plausible but incorrect value, which enters the dataset where a missing sample would not. Establishing equivalence requires a bridging sub-study in the trial’s own population with a pre-stated acceptable limit of agreement, not a manufacturer’s agreement data from a different population. Until such data exist, the conservative design keeps the primary endpoint on the reference method and uses home-collected values for secondary or trajectory analyses.
This cannot currently be answered from pooled evidence. The systematic review of decentralised trial methods identified 19,704 records, screened 18,553, assessed 237 full texts and included 45 trials in quantitative analysis, but concluded that the trials were too heterogeneous to meta-analyse. There is therefore no field-level estimate for retention, data quality, recruitment speed or cost. The reason is structural: included trials differ in which activities they moved, in condition, in technology and in what they measured. A specific decentralised element must be justified on mechanism and on the sponsor’s own feasibility data, and a vendor citing a retention improvement across decentralised trials is not citing this literature.
Because an in-person screening visit never comprised only the protocol-specified assessments. It was also an occasion for a clinician to notice something that no one had thought to measure, and the expert analysis of decentralised activities identified precisely this — remote screening without an in-person examination risks missing underlying conditions. Operationally, eligibility shifts from examined to reported, which changes both the safety profile of the enrolled population and its comparability with historical or concurrent site-screened cohorts. If screening is relocated, the protocol should state what replaces incidental clinical observation and should be explicit that eligibility now rests on participant report plus whatever remote assessment is specified.
As informative missingness, with the assumption stated and a sensitivity analysis pre-specified. The mechanism is the reason: device failures and collection failures occur more often among participants least able to troubleshoot them, so the gaps correlate with participant characteristics and often with the outcome. A default imputation under missing completely at random will therefore be biased in a predictable direction. The defensible approach is to record collection failures as a distinct category rather than subsuming them into missingness, to state the assumption under which the analysis is conducted and why, and to pre-specify at least one analysis under a missing-not-at-random assumption so that the dependence of the result on that assumption is visible.
Patients perceive advantages in it, but preference and decision-driver are not the same. A two-country qualitative study in Spain and Brazil — 47 interview participants comprising 37 patients, 2 caregivers and 8 healthcare professionals, plus a validation workshop with 32 more — identified comfort and convenience, better clinician-patient relationships and greater disease awareness as the main advantages of home- and remote-based testing. The same study found that convenience did not influence patients’ decisions in the way remote-testing arguments assume. For a protocol, this means that participant burden is a legitimate design objective but a weak basis for a retention assumption, and a trial justified primarily on convenience may not achieve the retention it projected.
Those for which the site was providing a room rather than a capability, and which do not feed eligibility or the primary endpoint. In practice, the adoption pattern across protocols is a reasonable guide to difficulty: telemedicine contact and patient-reported outcomes were relocated most easily, wearables and biomarker kits considerably less so, and home health visits least. Relocation should begin where nothing is physically handled and no clinical observation is lost; once the operational pattern is established, measurement can be relocated — with bridging data. For any activity affecting eligibility, the primary endpoint or safety reporting, the validation burden is higher and the sequencing should reflect that.
References
- U.S. Food and Drug Administration (CDER, CBER, CDRH, Oncology Center of Excellence). Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties. 2024. read 9 October 2026. fda.gov
- European Medicines Agency. ICH E6 Good clinical practice - Scientific guideline. European Medicines Agency. read 9 October 2026. ema.europa.eu
- Murciano-Gamborino C, Perez-Breva L, de Jong AJ, van Thiel GJM, Santa-Ana-Tellez Y, Boeckhout M, Siiskonen SJ, van Rijssel T, Gardarsdottir H, Fons-Martinez J, et al. SWOT analysis of decentralised clinical trials from an ethical, legal, regulatory and operational perspective. BMC Medical Ethics. 2026;27(1):57. doi:10.1186/s12910-026-01391-w read 9 October 2026. doi.org/10.1186/s12910-026-01391-w
- Adashi EY, Marks PW. Achieving Diversity Through Decentralization. Journal of General Internal Medicine. 2024;39(9):1744-1745. doi:10.1007/s11606-024-08780-0 read 9 October 2026. doi.org/10.1007/s11606-024-08780-0
- de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials. Therapeutic Innovation & Regulatory Science. 2024;58(3):483-494. doi:10.1007/s43441-024-00613-w read 9 October 2026. doi.org/10.1007/s43441-024-00613-w
- Ratitch B, Trigg A, Majumder M, Vlajnic V, Rethemeier N, Nkulikiyinka R. Clinical Validation of Novel Digital Measures: Statistical Methods for Reliability Evaluation. Digital Biomarkers. 2023;7(1):74-91. doi:10.1159/000531054 read 9 October 2026. doi.org/10.1159/000531054
- Mittermaier M, Venkatesh KP, Kvedar JC. Digital health technology in clinical trials. npj Digital Medicine. 2023;6:88. doi:10.1038/s41746-023-00841-8 read 9 October 2026. doi.org/10.1038/s41746-023-00841-8
- Lalanza S, Pena C, Bezos C, Yamauchi N, Taffner V, Rodrigues K, Garcia Manrique M, Rubio Jareno A, Lemos Gil A. Patient and Healthcare Professional Insights of Home- and Remote-Based Clinical Assessment: A Qualitative Study from Spain and Brazil to Determine Implications for Clinical Trials and Current Practice. Advances in Therapy. 2023;40(4):1670-1685. doi:10.1007/s12325-023-02441-0 read 9 October 2026. doi.org/10.1007/s12325-023-02441-0
- Rogers A, De Paoli G, Subbarayan S, Copland R, Harwood K, Coyle J, et al. A Systematic Review of Methods used to Conduct Decentralised Clinical Trials. British Journal of Clinical Pharmacology. 2022;88(6):2843-2862. doi:10.1111/bcp.15205 read 9 October 2026. doi.org/10.1111/bcp.15205
- de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Monitoring Lead to Higher Quality? An Analysis of Key Risk Indicator Outcomes. Therapeutic Innovation & Regulatory Science. 2022;57(2):295-303. doi:10.1007/s43441-022-00470-5 read 9 October 2026. doi.org/10.1007/s43441-022-00470-5
- de Jong AJ, Grupstra RJ, Santa-Ana-Tellez Y, Zuidgeest MGP, de Boer A, Gardarsdottir H. Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019-2020? A cross-sectional study in ClinicalTrials.gov. BMJ Open. 2022;12(8):e063236. doi:10.1136/bmjopen-2022-063236 read 9 October 2026. doi.org/10.1136/bmjopen-2022-063236
- de Jong AJ, Santa-Ana-Tellez Y, van Thiel GJMW, Zuidgeest MGP, Grobbee DE, Gardarsdottir H, et al. COVID-19 and the emerging regulatory guidance for ongoing clinical trials in the European Union. Clinical Pharmacology & Therapeutics. 2021;109:1517-1527. doi:10.1002/cpt.2225 read 9 October 2026. doi.org/10.1002/cpt.2225
- Cragg WJ, Hurley C, Yorke-Edwards V, Stenning SP. Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review. Clinical Trials. 2021;18(2):245-259. doi:10.1177/1740774520976561 read 9 October 2026. doi.org/10.1177/1740774520976561
- Marra C, Gordon WJ, Stern AD. Use of connected digital products in clinical research following the COVID-19 pandemic: a comprehensive analysis of clinical trials. BMJ Open. 2021;11:e047341. doi:10.1136/bmjopen-2020-047341 read 9 October 2026. doi.org/10.1136/bmjopen-2020-047341
- DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. The Lancet. 2020;395(10221):361-369. doi:10.1016/S0140-6736(19)33220-9 read 9 October 2026. doi.org/10.1016/S0140-6736(19)33220-9
- Inan OT, Tenaerts P, Prindiville SA, et al. Digitizing clinical trials. npj Digital Medicine. 2020;3:101. doi:10.1038/s41746-020-0302-y read 9 October 2026. doi.org/10.1038/s41746-020-0302-y
- Skelton E, Drey N, Rutherford M, Ayers S, Malamateniou C. Electronic consenting for conducting research remotely: a review of current practice and key recommendations for using e-consenting. International Journal of Medical Informatics. 2020;143:104271. doi:10.1016/j.ijmedinf.2020.104271 read 9 October 2026. doi.org/10.1016/j.ijmedinf.2020.104271
- Coravos A, Doerr M, Goldsack J, Manta C, Shervey M, Woods B, Wood WA. Modernizing and designing evaluation frameworks for connected sensor technologies in medicine. npj Digital Medicine. 2020;3:37. doi:10.1038/s41746-020-0237-3 read 9 October 2026. doi.org/10.1038/s41746-020-0237-3
- Brogger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online patient recruitment in clinical trials: systematic review and meta-analysis. Journal of Medical Internet Research. 2020;22:e22179. doi:10.2196/22179 read 9 October 2026. doi.org/10.2196/22179
- Marra C, Chen JL, Coravos A, Stern AD. Quantifying the use of connected digital products in clinical research. npj Digital Medicine. 2020;3:50. doi:10.1038/s41746-020-0259-x read 9 October 2026. doi.org/10.1038/s41746-020-0259-x
- Gerke S, Shachar C, Chai PR, Cohen IG. Regulatory, safety, and privacy concerns of home monitoring technologies during COVID-19. Nature Medicine. 2020;26:1176-1182. doi:10.1038/s41591-020-0994-1 read 9 October 2026. doi.org/10.1038/s41591-020-0994-1
- Wilkinson M, Young R, Harper B, Machion B, Getz K. Baseline assessment of the evolving 2017 eClinical landscape. Therapeutic Innovation & Regulatory Science. 2019;53:71-80. doi:10.1177/2168479018769292 read 9 October 2026. doi.org/10.1177/2168479018769292
- Coravos A, Goldsack JC, Karlin DR, Nebeker C, Perakslis E, Zimmerman N, Erb MK. Digital medicine: a primer on measurement. Digital Biomarkers. 2019;3:31-71. doi:10.1159/000500413 read 9 October 2026. doi.org/10.1159/000500413
- Noah B, Keller MS, Mosadeghi S, Stein L, Johl S, Delshad S, et al. Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials. npj Digital Medicine. 2018;1:20172. doi:10.1038/s41746-017-0002-4 read 9 October 2026. doi.org/10.1038/s41746-017-0002-4
- Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. New England Journal of Medicine. 2015;372(11):1031-1039. doi:10.1056/NEJMsa1409364 read 9 October 2026. doi.org/10.1056/NEJMsa1409364
- Rosa C, Campbell ANC, Miele GM, Brunner M, Winstanley EL. Using e-technologies in clinical trials. Contemporary Clinical Trials. 2015;45:41-54. doi:10.1016/j.cct.2015.07.007 read 9 October 2026. doi.org/10.1016/j.cct.2015.07.007
- European Parliament and Council of the European Union. Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. Official Journal of the European Union (CELEX 32014R0536). 2014. read 9 October 2026. eur-lex.europa.eu
- Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11(1):32. doi:10.1186/1745-6215-11-32 read 9 October 2026. doi.org/10.1186/1745-6215-11-32
- Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110. read 9 October 2026. cobe.paginas.ufsc.br
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD read 9 October 2026. doi.org/10.1136/bmj.39335.541782.AD
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18(6):800-804. doi:10.1097/EDE.0b013e3181577654 read 9 October 2026. doi.org/10.1097/EDE.0b013e3181577654
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence. Pubrica. https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/
Pubrica Academy. “Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence.” Pubrica, 9 Oct. 2026, pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/.
Pubrica Academy (2026) Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence. Pubrica. Available at: https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/ (Accessed: 15 October 2026).
Pubrica Academy. “Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence.” Pubrica. October 9, 2026. https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/
Pubrica Academy, ‘Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/> accessed 15 October 2026.
Pubrica Academy. Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/
Pubrica Academy, “Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/
@misc{significant_advancement_of_home_diagno_2026,
author = {{Pubrica Academy}},
title = {Home Diagnostics in Clinical Trials: Adoption, Limitations and Evidence},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/medical-writing/significant-advancement-of-home-diagnostics-in-the-clinical-trial/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Home and remote activity specification sheet
One sheet should be completed for each activity to be moved away from the investigator site, before the protocol is drafted. The row that is most difficult to complete is usually the one that will cause a deviation.
HOME / REMOTE ACTIVITY SPECIFICATION
Trial: ______________________ Activity: ______________________
Currently performed: [ ] at site [ ] already remote
Proposed location: [ ] participant home [ ] local facility
[ ] home visit by trial staff [ ] other: _____
1. WHAT THE SITE WAS PROVIDING BEYOND A ROOM
[ ] trained observation replaced by: ___________________
[ ] controlled handling replaced by: ___________________
[ ] identity verification replaced by: ___________________
[ ] immediate clinical response replaced by: _______________
[ ] incidental examination replaced by: ___________________
Anything NOT replaced: ______________________________________
2. CRITICALITY
Does this activity feed:
primary endpoint? [ ] yes [ ] no
eligibility? [ ] yes [ ] no
safety reporting? [ ] yes [ ] no
If any yes, bridging/validation data are mandatory, not optional.
3. MEASUREMENT SPECIFICATION (for any measured quantity)
Quantity and units: ______________________
Matrix / specimen / signal: ______________________
Time of day / physiological state required: ______________
Stability window: ______ hours at ______ to ______ degrees C
Real courier / upload timeline, worst case: ______________
Device or kit, with version: ______________________
4. ACCEPTANCE CRITERIA AND FAILURE RULE
Accepted if: ________________________________________________
Rejected if: ________________________________________________
On failure: [ ] one repeat within ____ days
[ ] record as collection failure (not missing)
[ ] escalate to site
Who applies the rule: ______________________
5. AGREEMENT WITH THE REFERENCE METHOD
Reference method: ______________________
Bridging data source: [ ] sub-study in this population, n = ____
[ ] external data - population: ________
Acceptable limit of agreement, stated in advance: ___________
If agreement not yet established, endpoint role of this
measurement: [ ] secondary only [ ] exploratory only
6. MISSINGNESS
Expected failure rate: ______%
Assumed mechanism: __________________________________________
Why: ________________________________________________________
Pre-specified sensitivity analysis: __________________________
7. PARTICIPANT SUPPORT AND SAFETY
Training method: ______________ teach-back recorded? [ ] yes
Contact route when the kit fails: ___________________________
Hours of availability: ______________
Clinically actionable range: ______________________
Reported to site within: ______ working day(s)
Managed under protocol section: ______
Participants without required devices/connectivity:
alternative route: __________________________________________
8. HYBRID INTERFACE
Which visits remain on site: ________________________________
How home and site values are reconciled if they disagree:
____________________________________________________________
Recorded in the same dataset with a source flag? [ ] yes
9. JUSTIFICATION (be specific; convenience is not a retention claim)
Primary reason for moving this activity: ____________________
Evidence for that reason: ___________________________________
Retention assumption made in the sample size? [ ] none
[ ] yes - basis: __________________________________________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica specifies home and remote measurements to a level at which both a laboratory and a statistician can work from them: stability windows against actual courier timelines, acceptance criteria, failure rules, and bridging sub-studies with the limit of agreement stated before the data are seen. Pubrica also writes the handling of missing data into the analysis plan as informative rather than default, and designs the hybrid interface so that home-collected and site-collected values carry a source flag and a documented reconciliation rule. Where a protocol justifies decentralisation on the grounds of participant burden, Pubrica states clearly what the evidence does and does not support regarding retention.